# President Trump’s Administration Reclassifies State-Licensed Medical Marijuana as Lower-Risk Drug > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/state-licensed-medical-marijuana-reclassified-lower-risk-drug/ > **Published:** 2026-04-26T18:18:48-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:10:09-04:00 > **Clinical Summary:** Explore how state-licensed medical marijuana reclassified as lower-risk drug impacts clinical research and patient access under President Trump's administration. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic Policy[Medical Cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/)RegulationResearchFederal Law Why This Matters Reclassification of cannabis to a lower schedule could significantly impact clinical practice by reducing regulatory barriers to research and potentially expanding access to pharmaceutical-grade cannabis products. This administrative change may accelerate the development of evidence-based treatment protocols that clinicians have been waiting for. Clinical Summary The Trump administration has reportedly moved to reclassify state-licensed medical marijuana to a lower controlled substance schedule, reducing its regulatory classification from the current Schedule I status. This change would acknowledge accepted medical use and potentially lower the regulatory burden on medical cannabis programs. The reclassification could facilitate expanded [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) and may influence prescribing practices, though specific implementation details and timeline remain unclear from available reporting. Dr. Caplan’s Take “This is the kind of regulatory alignment we’ve needed to advance legitimate [medical cannabis research](https://cedclinic.com/cannabis-varieties-differentiation-cannabinomics/) and clinical applications. The real question is whether this translates into meaningful changes in research funding and pharmaceutical development pipelines.” Clinical Perspective 🧠 Clinicians should monitor how this reclassification affects state medical cannabis programs and research opportunities in their jurisdictions. The change may lead to improved product standardization and quality control, but practitioners should continue to rely on existing evidence-based guidelines rather than assuming expanded access equals expanded indications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20State-licensed%20medical%20marijuana%20reclassified%20as%20lower-risk%20drug%20by%20President%20Trump%E2%80%99s%20administration%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fstate-licensed-medical-marijuana-reclassified-as-lower-risk-drug-by-president-tr%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fstate-licensed-medical-marijuana-reclassified-as-lower-risk-drug-by-president-tr%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20State-licensed%20medical%20marijuana%20reclassified%20as%20lower-risk%20drug%20by%20President%20Trump%E2%80%99s%20administration%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fstate-licensed-medical-marijuana-reclassified-as-lower-risk-drug-by-president-tr%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.youtube.com/shorts/gIOe1CP2K94](https://www.youtube.com/shorts/gIOe1CP2K94) Table of Contents - [FAQ](#FAQ)[What is the CED Clinical Relevance rating system?](#What_is_the_CED_Clinical_Relevance_rating_system) - [What does “Notable Clinical Interest” mean for cannabis research?](#What_does_8220Notable_Clinical_Interest8221_mean_for_cannabis_research) - [What areas does this cannabis news cover?](#What_areas_does_this_cannabis_news_cover) - [Who is the target audience for this information?](#Who_is_the_target_audience_for_this_information) - [How should healthcare providers use this type of information?](#How_should_healthcare_providers_use_this_type_of_information) - [Related](#Related) ## FAQ #### What is the CED Clinical Relevance rating system? The CED Clinical Relevance system appears to be a rating framework that categorizes clinical developments by their significance. Rating #76 indicates “Notable Clinical Interest” for emerging findings or policy developments that warrant close monitoring by healthcare professionals. #### What does “Notable Clinical Interest” mean for cannabis research? This designation suggests the cannabis-related development represents emerging findings or policy changes that have potential clinical implications. It indicates the information is worth monitoring closely by medical professionals, though it may not yet represent established clinical practice. #### What areas does this cannabis news cover? Based on the tags shown, this news covers multiple aspects including policy developments, medical cannabis applications, regulatory changes, and research findings. This multidisciplinary approach suggests comprehensive coverage of cannabis-related clinical and policy developments. #### Who is the target audience for this information? The content appears to be aimed at healthcare professionals, particularly those working in clinical settings who need to stay informed about cannabis policy and research developments. The clinical relevance rating system suggests it’s designed for medical practitioners and researchers. #### How should healthcare providers use this type of information? Healthcare providers should use this as monitoring information to stay current with evolving cannabis policy and research. Since it’s marked as “emerging findings,” providers should continue following established clinical guidelines while staying informed about developing trends in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/). [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Administration to reclassify medical marijuana restrictions, expanding research potential](https://cedclinic.com/trump-administration-cannabis-research-expansion/) Learn how the Trump administration's reclassification efforts aim to expand medical marijuana research and reduce regulatory hurdles. [Read More](https://cedclinic.com/trump-administration-cannabis-research-expansion/) [Trump administration reclassifies medical marijuana as Schedule III – Quartz](https://cedclinic.com/medical-marijuana-schedule-iii-regulatory-changes/) An in-depth look at the federal reclassification of medical marijuana and its implications for clinical practice and research. [Explore Article](https://cedclinic.com/medical-marijuana-schedule-iii-regulatory-changes/) [State-licensed medical marijuana reclassified to Schedule III drug. What it means for Kentucky – AOL](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) This article discusses the effects of medical marijuana's Schedule III reclassification on state programs and patient access. [Learn More](https://cedclinic.com/schedule-iii-cannabis-reclassification-clinical-trials-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).